PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, will issue a news release at 7:30 a.m. Eastern time on November 12 announcing the findings of the Data Monitoring Committee planned, pre-specified interim analysis of the aclerastide Phase 3 clinical trials for the closure of diabetic foot ulcers. A conference call will be held to discuss the findings beginning at 8:30 a.m. Eastern time that same day.
Help employers find you! Check out all the jobs and post your resume.
